

Phone: 1-800-809-1265 Fax: 1-866-872-8920

REQUIRED: TB screening for new start patients

HBV screening/labs as required by payor

Referral Status:	M	RN:
New referral	Order change	Order Renewal
Patient preferred clinic:		

Continue current order until insurance approved

Cimzia® (certolizumab pegol) Standard Plan of Treatment for Rheumatology & Dermatology

PATIENT DEMOGRAPHICS:									
Date of Referral:				Patient's Phone:					
Patient Name:			Address:						
Date of Birth:				City, State, Zip:					
Height in inches:	Weight:	LB or	KG	Gender:	/	Allergies:		See list	NDKA

DIAGNOSIS: (PLEASE COMPLETE 2 ND AND 3 RD DIGITS TO COMPLETE ICD 10 FOR BILLING)							
	M05 Rheumatoid Arthritis with rheumatoid factor		M45.A Non-radiographic axial spondyloarthritis				
	M06 Rheumatoid Arthritis without rheuma	atoid factor	L40.0 - Psoriasis vulgaris				
	M45 Ankylosing Spondylitis		L40.5 Arthropathic psoriasis				
	M46.8 Other specified inflammatory spondy	ylopathies	L40.9 - Psoriasis, unspecifed				
	Other:						
REQ	REQUESTED DOCUMENTATION: PREVIOUS ADMINISTRATION: HAS THIS PATIENT TAKEN THIS MEDICATION BEFORE?						
1	Insurance information	IF NO:	IF YES:				
2	Most recent History & Physical		LAST INJECTION DATE:				
3	Full medication list	REQUIRED WASHOUT	NEXT INJECTION DATE:				
4	Tried and failed therapies	THERAPY:	IF ORDER CHANGE:				

MEDICATION ORDERS:

NOTE: Patient may be ineligible to receive certolizumab pegol if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, new or worsening symptoms of CHF, new-onset or deterioration neurological changes, and/or surgery.

DOSE/FREQUENCY:

Induction: Cimzia[®] (certolizumab pegol) 400mg at week 0, week 2, week 4, and maintenance as indicated below Maintenance: Cimzia[®] (certolizumab pegol) 200mg every 2 weeks

Maintenance: Cimzia[®] (certolizumab pegol) 400mg every 4 weeks

Administer as 2 divided subcutaneous injections to separate sites in the abdomen or thigh only

SPECIAL ORDERS:

5

6

Prescriber confirms that the patient has been evaluated and screened for the presence of hepatitis B virus (HBV) prior to initiating treatment. Prescriber to monitor patient for symptoms of HBV and TB infection and reactivation as clinically appropriate.

Refills x 12 months unless noted otherwise here:

ADVERSE REACTION & ANAPHYLAXIS ORDERS:

Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing adverse reaction orders, which can be found at our website or scan here.



PRESCRIBER INFORMATION:						
PROVIDER NAME:		PHONE:				
ADDRESS:		FAX:				
CITY, STATE, ZIP:	NPI:					
PRESCRIBER SIGNATURE: (No stamp signatures)				DATE		
Dispense as written/Brand medically necessary		Subst	itution permitted			